Literature DB >> 1874022

Subtypes of intestinal metaplasia and gastric carcinoma. A clinicoendoscopic follow-up of 112 cases.

D C Fang1, W W Liu.   

Abstract

Nine tumor-associated antigens (MG7-, MGdl-, MC3-corresponding antigens, CEA, P21ras, Sialoglycoprotein, CA 19-9-like, Sialo-Tn and Le8-like antigens) were investigated on biopsy specimens of different types of intestinal metaplasia (types I, II and III) taken from 112 patients with benign gastric conditions. The incidence of positive staining for 9 antigens except for P21ras in type III intestinal metaplasia was significantly higher than that in types I and II (P less than 0.05-0.01). These 112 patients were clinicoendoscopically followed up for 15-70 months. Five of them were found to develop gastric carcinomas within 25-60 months, giving a cancer detection rate of 4.5%. They were detected from type III (16.1%) patients, but none was found in patients of types I and II, and the differences were significant (P less than 0.05-0.01). Our results indicate that type III intestinal metaplasia has a higher potentiality in developing malignancy and that MG7, MGd1, MC3, CEA, CA19-9-like and Sialo-Tn antigens are valuable tumor markers in defining the high-risk group of gastric carcinoma.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1874022

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


  2 in total

1.  Expression of gastric cancer-associated MG7 antigen in gastric cancer, precancerous lesions and H. pylori -associated gastric diseases.

Authors:  Dong-Li Guo; Ming Dong; Lan Wang; Li-Ping Sun; Yuan Yuan
Journal:  World J Gastroenterol       Date:  2002-12       Impact factor: 5.742

2.  Gastric Cancer Risk of Intestinal Metaplasia Subtypes: A Systematic Review and Meta-Analysis of Cohort Studies.

Authors:  Sijing Du; Yang Yang; Shuangshuang Fang; Song Guo; Chuchu Xu; Ping Zhang; Wei Wei
Journal:  Clin Transl Gastroenterol       Date:  2021-10-01       Impact factor: 4.488

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.